Get to know our clinical trials
Ensayo de Debio 0123 en combinación con temozolomida en participantes adultos con glioblastoma recurrente o progresivo y de Debio 0123 en combinación con temozolomida y radioterapia en participantes adultos con glioblastoma de diagnóstico reciente
SE TRATA DE UN ESTUDIO EN FASE 1/2 DE DEBIO 0123 EN COMBINACIÓN CON TEMOZOLOMIDA PARA EL TRATAMIENTO DEL GLIOBLASTOMA (GBM) RECURRENTE O PROGRESIVO Y DE DEBIO 0123 EN COMBINACIÓN CON TEMOZOLOMIDA Y RADIOTERAPIA PARA EL TRATAMIENTO DEL GLIOBLASTOMA DE DIAGNÓSTICO RECIENTE
Technical Summary
- A PHASE 1/2 OPEN-LABEL STUDY OF DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE IN ADULT PARTICIPANTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA AND OF DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE AND RADIOTHERAPY IN ADULT PARTICIPANTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
- Code EudraCT: 2022- 502156-31
- Protocol number: Debio 0123-GBM-105
- Promoter: Debiopharm International S.A.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.